235 related articles for article (PubMed ID: 29630107)
1. LINC00963 promotes hepatocellular carcinoma progression by activating PI3K/AKT pathway.
Wu JH; Tian XY; An QM; Guan XY; Hao CY
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1645-1652. PubMed ID: 29630107
[TBL] [Abstract][Full Text] [Related]
2. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of lncRNA FER1L4 suppresses the proliferation and migration of the hepatocellular carcinoma via regulating PI3K/AKT signal pathway.
Wang X; Dong K; Jin Q; Ma Y; Yin S; Wang S
J Cell Biochem; 2019 Apr; 120(4):6781-6788. PubMed ID: 30382631
[TBL] [Abstract][Full Text] [Related]
4. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway.
Li Y; Ye Y; Feng B; Qi Y
J Cell Biochem; 2017 Dec; 118(12):4498-4507. PubMed ID: 28464252
[TBL] [Abstract][Full Text] [Related]
5. LINC01133 aggravates the progression of hepatocellular carcinoma by activating the PI3K/AKT pathway.
Zheng YF; Zhang XY; Bu YZ
J Cell Biochem; 2019 Mar; 120(3):4172-4179. PubMed ID: 30548306
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
[TBL] [Abstract][Full Text] [Related]
7. DUXAP10 inhibition attenuates the proliferation and metastasis of hepatocellular carcinoma cells by regulation of the Wnt/β-catenin and PI3K/Akt signaling pathways.
Han K; Li C; Zhang X; Shang L
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30996112
[TBL] [Abstract][Full Text] [Related]
8. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
9. MEG3 promotes liver cancer by activating PI3K/AKT pathway through regulating AP1G1.
Sun Y; Cao FL; Qu LL; Wang ZM; Liu XY
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1459-1467. PubMed ID: 30840267
[TBL] [Abstract][Full Text] [Related]
10. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of LncRNA NR027113 inhibits cell proliferation and metastasis via PTEN/PI3K/AKT signaling pathway in hepatocellular carcinoma.
Chen Z; Zhou ZY; He CC; Zhang JL; Wang J; Xiao ZY
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7222-7232. PubMed ID: 30468465
[TBL] [Abstract][Full Text] [Related]
12. PAQR4 promotes the development of hepatocellular carcinoma by activating PI3K/AKT pathway.
Zhao G; Shi X; Sun Z; Zhao P; Lu Z
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1602-1613. PubMed ID: 34718369
[TBL] [Abstract][Full Text] [Related]
13. LINC02154 promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing SPC24 promoter activity and activating the PI3K-AKT signaling pathway.
Yue H; Wu K; Liu K; Gou L; Huang A; Tang H
Cell Oncol (Dordr); 2022 Jun; 45(3):447-462. PubMed ID: 35543858
[TBL] [Abstract][Full Text] [Related]
14. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
[TBL] [Abstract][Full Text] [Related]
15. STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway.
Wu JZ; Jiang N; Lin JM; Liu X
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2977-2985. PubMed ID: 32271415
[TBL] [Abstract][Full Text] [Related]
16. CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis.
Ma XL; Shen MN; Hu B; Wang BL; Yang WJ; Lv LH; Wang H; Zhou Y; Jin AL; Sun YF; Zhang CY; Qiu SJ; Pan BS; Zhou J; Fan J; Yang XR; Guo W
J Hematol Oncol; 2019 Apr; 12(1):37. PubMed ID: 30971294
[TBL] [Abstract][Full Text] [Related]
17. Oncogene Delta/Notch-Like EGF-Related Receptor Promotes Cell Proliferation, Invasion, and Migration in Hepatocellular Carcinoma and Predicts a Poor Prognosis.
Liang Y; Luo H; Zhang H; Dong Y; Bao Y
Cancer Biother Radiopharm; 2018 Nov; 33(9):380-386. PubMed ID: 30235011
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-8 promotes integrin β3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma.
Sun F; Wang J; Sun Q; Li F; Gao H; Xu L; Zhang J; Sun X; Tian Y; Zhao Q; Shen H; Zhang K; Liu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):449. PubMed ID: 31684995
[TBL] [Abstract][Full Text] [Related]
19. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
20. LINC00707 promotes hepatocellular carcinoma progression through activating ERK/JNK/AKT pathway signaling pathway.
Wang J; Luo Z; Yao T; Li W; Pu J
J Cell Physiol; 2019 May; 234(5):6908-6916. PubMed ID: 30317590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
